St. Jude Warning Letter Spotlights CAPA Flaws At CardioMEMS Unit
This article was originally published in The Gray Sheet
The warning letter highlights validation and recordkeeping problems at the Atlanta manufacturing facility for the CardioMEMS heart failure remote monitoring system, but it is not expected to affect device availability.
You may also be interested in...
St. Jude Medical's CardioMEMS unit cited for quality system reg violations; complaints weren't evaluated for MDR-reportability at maker of wound dressings and gauze; and more. Two device warning letters were listed by FDA this week.
Improving outcomes, reducing costs, and cutting readmissions are front and center for St. Jude Medical as it moves into new areas of cardio technology that suit the changing needs of both providers and patients.
NeuroTherm makes devices for radiofrequency ablation of nerves in painful facet joints in the neck or back to treat chronic pain. Although it markets neurostimulators, St. Jude currently does not sell any devices in the radio-frequency ablation segment of the pain-therapy market.